Drug Res (Stuttg) 2013; 63(07): 362-369
DOI: 10.1055/s-0033-1341463
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Novel Quinuclidinone Derivatives Induce Apoptosis in Lung Cancer via Sphingomyelinase Pathways

A. Malki
1   Biochemistry department, Faculty of Science, Alexandria University, Alexandria, Egypt
,
L. Fathy
2   Chemistry department, Faculty of Science, Alexandria University, Alexandria, Egypt
,
E.S H. El Ashry
2   Chemistry department, Faculty of Science, Alexandria University, Alexandria, Egypt
› Author Affiliations
Further Information

Publication History

received 07 March 2012

accepted 06 March 2013

Publication Date:
12 April 2013 (online)

Abstract

We previously reported novel quinuclidinone analogs which induced apoptosis in lung and breast cancer cells. In this study, we designed and synthesized novel quinuclidinone analogs that showed cytotoxicity in lung cancer cells. The effects of these analogs were studied in H1299 human large cell lung carcinoma cells that are null for p53 and normal lung epithelial cell lines (NL-20). The effects of the analogs were investigated by MTT assay, ELISA based apoptotic assay, TUNEL assay, sphingomylinase activity, flow cytometry and western blot analysis. Our data indicated that derivatives 4 and 6 decreased cell proliferation and induced apoptosis in H1299 cells more than NL-20 cells. Derivatives 4 and 6 reduced percent of cells in G2/M phase in H1299 cells more than NL-20 cells and these results were confirmed by increased expression levels of cyclin E. Furthermore, derivatives 4 and 6 increased sphingomyelinase activity, caspase-8, and caspase-9 and JNK-1 expression level in H1299. Additionally, derivatives 4 and 6 induced Procaspase-3, PARP-1 cleavage, and increased caspase-3 activity. All these results confirm that our quinuclidinone derivatives provoke cytotoxicity in lung cancer cells through the interplay of key apoptosis molecules in different compartments of the cell beginning with an increase in sphingomyelinase activity.